Ozempic And Criminology: Analyzing Data From 821 Adults Who Had Used A GLP-1 Receptor Agonist, Drawn From A Larger 2025 Survey Of 7,521 US Adults, Lead Author Daniel Semenza And Coauthor Christopher Thomas Found The Connection Between Alcohol Use And Violence Was Also Weaker Among Current Users, Though Less Consistently So, Suggesting These Drugs May Function Somewhat Like Cognitive Behavioral Therapy For Impulse Control
According to ScienceDaily, reporting on a new Rutgers University study published in the journal Criminology, the well-established statistical link between impulsivity and violent behavior was approximately 62% weaker among adults currently using a GLP-1 receptor agonist medication, such as Ozempic or Wegovy, compared to adults who had used one in the past but stopped.
The connection between alcohol consumption and violent behavior was also weaker among current users, by roughly 52%, though that particular finding held up less consistently across the researchers’ additional sensitivity analyses.
A drug class already under heavy behavioral scrutiny.
GLP-1 medications, originally developed and approved for managing type 2 diabetes, became a cultural and medical phenomenon once their dramatic weight-loss effects became widely known. What has emerged more gradually, and far more quietly, is a growing body of research suggesting these drugs may influence brain function well beyond appetite regulation.
Earlier ScienceDaily coverage this year has linked the same drug class to lower depression and anxiety risk, lower rates of addiction and overdose, and even improved heart recovery after a heart attack. This new study extends that pattern into a domain few people would have expected a weight-loss drug to touch: the psychology of violent behavior.
How the study was actually built.
Semenza and Thomas worked from a 2025 survey of 7,521 adults across the United States, then narrowed their primary analysis to 821 respondents who reported having used a GLP-1 medication at some point. Within that group, the researchers compared people currently taking the medication against people who had used it previously but were no longer taking it.
Violent behavior itself was measured using a validated self-report instrument covering specific actions including fighting, assault, and robbery, rather than a vague or self-diagnosed sense of aggression. The researchers then tested how strongly two well-known predictors of violence, impulsivity and alcohol consumption, were statistically connected to that violent behavior, and whether current GLP-1 use changed the strength of those connections.
The headline number, and what it actually means.
Across the full sample, both higher impulsivity and heavier alcohol use were strongly associated with violent behavior, a finding entirely consistent with decades of existing criminology research. The notable twist was that among people currently taking a GLP-1 medication, the impulsivity-to-violence connection was substantially weaker, by the researchers’ calculation, around 62% weaker than among former users.
Semenza, who directs research at the Rutgers School of Public Health’s New Jersey Gun Violence Research Center, has noted that it is important to understand all of their potential behavioral effects.
That framing matters because it places this finding inside a public safety conversation rather than purely a pharmacology one. The study is not claiming GLP-1 drugs make impulsive people calm.
It is claiming something narrower and arguably more interesting: that impulsivity may be less likely to translate into a violent act when someone is actively on the medication.
Why the alcohol finding deserves a more cautious read.
The alcohol-violence connection followed a similar pattern, weaker among current users by roughly 52%, but the researchers were explicit that this particular result did not hold up as consistently once they ran additional sensitivity analyses.
In plain terms, that means the alcohol finding is real in this dataset but shakier under scrutiny, the kind of result that deserves genuine interest without being treated as settled. Good science reporting has to hold both of these things at once: the finding is worth taking seriously, and it is also less robust than the headline impulsivity number.
The proposed mechanism, explained without overselling it.
Thomas offered a useful analogy for what might be happening biologically and behaviorally. He described the pattern as consistent with these medications working like cognitive behavioral therapy, weakening the path from impulse to action rather than eliminating impulsivity itself.
That distinction is the single most important sentence in the entire study. The researchers are not suggesting GLP-1 drugs make someone less impulsive as a personality trait.
They are suggesting something more specific, that the medication may interrupt the pipeline between feeling an impulsive urge and actually acting on it, similar to how structured behavioral therapy trains people to create space between stimulus and response.
GLP-1 receptors are known to be present in brain regions tied to reward processing and impulse regulation, which gives this theory some biological plausibility, but plausibility is not proof.
The limitation the researchers themselves insist on.
This is the section that matters most for any reader tempted to draw a bigger conclusion than the data supports. The study is observational and cross-sectional, meaning it captured a single snapshot in time and compared groups of people who were already different from each other in ways the researchers cannot fully control for.
People who stay on a GLP-1 medication long enough to become a “current user” may differ systematically from people who stopped, in income, healthcare access, baseline health, motivation, or a dozen other factors that could independently affect both violent behavior and medication adherence.
The researchers explicitly state that this design can only identify associations, not cause-and-effect relationships, and that determining whether GLP-1 medications truly lower violence risk will require future longitudinal studies that track the same people over time, and ideally experimental studies that can isolate the medication’s effect from everything else.
What this means if it holds up.
GLP-1 medications are now used by tens of millions of people worldwide and that number is rising quickly. If a genuine causal effect on impulsive violence is eventually confirmed through better-designed research, the public health implications would be significant, potentially relevant to domestic violence reduction, criminal justice and reentry programs, and clinical decisions for patients with documented impulse control difficulties.
But that is a large conditional sitting on top of a single observational study, and treating it as settled science today would be irresponsible, both to the researchers, who were careful not to overclaim, and to anyone who might misread this as license to use these medications as an unsupervised substitute for therapy, anger management, or psychiatric care.
The editorial verdict.
This finding deserves genuine scientific curiosity rather than either dismissal or hype. A 62% weakening of one of criminology’s most reliable predictors is too large a number to wave away as noise, and the underlying biological story, a hormone system already known to touch reward and impulse circuitry doing exactly what reward and impulse research would predict, is coherent rather than far-fetched.
At the same time, the honest framing is that this is one observational study awaiting replication, not a breakthrough treatment for violence. The right reaction from clinicians, policymakers, and the public is the same reaction good science always deserves: take the signal seriously enough to fund the follow-up research that can actually test causation, and resist the urge to turn a 62% statistical association into a headline that promises more than the data has earned.
To check out our previous coverage on health, medicine, and behavioral science, read our articles here.
This article discusses research on violent behavior and medication. It is intended for general informational purposes and is not medical advice; anyone with questions about GLP-1 medications, impulse control, or violent thoughts or behavior should speak with a qualified healthcare provider.
